Reactivation of TCF/Nrf1 during treatment with proteasome inhibitors results in increased proteasome synthesis—known as the bounce-back response—eliciting resistance to proteasome inhibitors in MM [92]. The gene discussed is NRF1; the disease is Miyoshi myopathy.